Colistimethate sodium inhaled - Zambon

Drug Profile

Colistimethate sodium inhaled - Zambon

Alternative Names: Inhaled colistimethate sodium - Zambon; Promixin; ZP-044

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator Profile Pharma
  • Developer Zambon SpA
  • Class Antibacterials; Polymixins
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystic fibrosis-associated respiratory tract infections
  • Phase III Pseudomonal infections

Most Recent Events

  • 13 Mar 2017 Phase-III clinical trials in Pseudomonal infections in Spain (Inhalation) (EudraCT2015-002743-33)
  • 27 Jun 2015 Clinical development for Non-cystic fibrosis bronchiectasis and Pseudomonal infections is ongoing
  • 10 Jun 2013 Zambon signs collaboration agreement with Philips for the use of I-neb® Adapted Aerosol Derlivery system with inhaled colistimethate sodium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top